Department of Occupational and Environmental Dermatology, Skåne University Hospital, Lund University, Malmö, Sweden.
Department of Dermatology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Contact Dermatitis. 2020 May;82(5):283-289. doi: 10.1111/cod.13483. Epub 2020 Mar 20.
Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and methylisothiazolinone (MI) are tested to detect contact allergy to these isothiazolinones.
To study if an aqueous patch test preparation with MCI and MI in a mix of 0.015% and 0.2%, respectively, detects more contact allergies than the commonly used preparations of MCI/MI in 0.02% aq. and MI in 0.2% aq.
A total of 1555 patients with dermatitis in five Swedish dermatology departments were tested consecutively with MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq.
The share of contact allergy to MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. varied in the test centers between 7.9% and 25.9%, 3.2% and 10.3%, and 5.8% and 12.3%, respectively. MCI/MI 0.215% aq. detected significantly more patch-test positive individuals than both MCI/MI 0.02% aq. (P < .001) and MI 0.2% aq. (P < .001), as well as either one of MCI/MI and MI (P < .001). In the patients only reacting to MCI/MI 0.215% aq., 57.7% were recorded as having a dermatitis that was explained or aggravated by exposure to either MCI/MI or MI.
The results speak in favor of replacing the preparations MCI/MI 0.02% aq. and MI 0.2% aq. with MCI/MI 0.215% aq. as the screening substance in the Swedish baseline series, which has been implemented in 2020.
甲基氯异噻唑啉酮/甲基异噻唑啉酮（MCI/MI）和甲基异噻唑啉酮（MI）用于检测对这些异噻唑啉酮的接触过敏。
研究在 0.015%和 0.2%的混合液中分别使用 MCI 和 MI 的水性贴剂试验制剂是否比常用的 0.02% MCI/MI 和 0.2% MI 制剂检测到更多的接触过敏。
在瑞典的五个皮肤科部门，对 1555 名患有皮炎的患者进行了连续测试，使用了 MCI/MI 0.215% aq、MCI/MI 0.02% aq 和 MI 0.2% aq。
在测试中心，MCI/MI 0.215% aq、MCI/MI 0.02% aq 和 MI 0.2% aq 的接触过敏率在 7.9%至 25.9%、3.2%至 10.3%和 5.8%至 12.3%之间变化。MCI/MI 0.215% aq 比 MCI/MI 0.02% aq（P<.001）和 MI 0.2% aq（P<.001）以及 MCI/MI 和 MI 中的任何一种（P<.001）都能更显著地检测到贴剂阳性个体。在仅对 MCI/MI 0.215% aq 反应的患者中，57.7%的患者记录为接触 MCI/MI 或 MI 导致或加重的皮炎。
结果表明，在瑞典基础系列中，应将 MCI/MI 0.02% aq 和 MI 0.2% aq 替换为 MCI/MI 0.215% aq 作为筛选物质，该系列已于 2020 年实施。
